Read-Gene SA

{
  "main_header": {
    "sid": 1140337,
    "name": "Read-Gene SA",
    "stock_name": "Read-Gene SA",
    "full_name": "Read-Gene SA",
    "name_url": "stocks-analysis/read-gene-sa",
    "exchange": 165,
    "exchangecode": "WAR",
    "country_id": 44,
    "currency": "PLN",
    "cmp": "5.62",
    "chg": 0.04,
    "chgp": "0.72%",
    "dir": 1,
    "prev_price": "5.58",
    "mcapval": "",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2320,
    "indexname": "Poland WIG",
    "isin": "PLRADGN00014",
    "curr_date": "Feb 13",
    "curr_time": "",
    "bse_nse_vol": "136 ",
    "exc_status": "Active",
    "traded_date": "Feb 13, 2026",
    "traded_date_str": "2026 02 13",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/read-gene-sa-1140337-165&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Read-Gene SA Reports Mixed Financial Results Amidst Market Volatility",
        "link": "https://www.marketsmojo.com/news/mojo-premium/read-gene-sa-joins-momentum-now-strategy-due-to-strong-financial-indicators-3790985",
        "imagepath": "",
        "date": "2026-01-13 15:36:08",
        "description": "<p><strong>Read-Gene SA</strong>, a micro-cap company in the Pharmaceuticals & Biotechnology sector, has recently released its financial results for the quarter ending June 2025. The performance has been characterized by significant fluctuations, reflecting the challenges faced in the current market environment.</p>\n\n<p>Despite the overall negative financial performance, <strong>Read-Gene SA</strong> reported some noteworthy metrics. The operating cash flow reached its highest level at PLN 5.11 MM, indicating a strong liquidity position. Additionally, net sales for the half-year period grew by 37.3%, amounting to PLN 6.99 MM, showcasing the company’s ability to increase revenue even amidst adverse conditions.</p>\n\n<p>However, the return on capital employed (ROCE) for the half-year was recorded at -9.22%, highlighting ongoing challenges in effectively utilizing capital. On a positive note, the company experi..."
      }
    ],
    "total": 2,
    "sid": "1140337",
    "stock_news_url": "https://www.marketsmojo.com/news/read-gene-sa-1140337"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Read-Gene SA Reports Mixed Financial Results Amidst Market Volatility

2026-01-13 15:36:08

Read-Gene SA, a micro-cap company in the Pharmaceuticals & Biotechnology sector, has recently released its financial results for the quarter ending June 2025. The performance has been characterized by significant fluctuations, reflecting the challenges faced in the current market environment.

Despite the overall negative financial performance, Read-Gene SA reported some noteworthy metrics. The operating cash flow reached its highest level at PLN 5.11 MM, indicating a strong liquidity position. Additionally, net sales for the half-year period grew by 37.3%, amounting to PLN 6.99 MM, showcasing the company’s ability to increase revenue even amidst adverse conditions.

However, the return on capital employed (ROCE) for the half-year was recorded at -9.22%, highlighting ongoing challenges in effectively utilizing capital. On a positive note, the company experi...

Read full news article

View All News